GCM
CATX icon

Graham Capital Management’s Perspective Therapeutics CATX Stock Holding History

Graham Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Buy
+11,713
New +$44.3K ﹤0.01% 1208
2026
Q1 		– Sell
-80,193
Closed -$221K – 1198
2025
Q4 		$221K Buy
80,193
+34,836
+77% +$99.4K 0.01% 1003
2025
Q3 		$156K Buy
+45,357
New +$165K ﹤0.01% 1111

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Graham Capital Management's CATX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 11,713 shares worth $39.9K. The stake represents ﹤0.01% of the portfolio and ranks #1208 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in CATX as recently as Q4 2025.

Graham Capital Management first reported a position in CATX in Q3 2025 and has held it in 3 quarters since. The position peaked at $221K in Q4 2025. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Graham Capital Management held 11,713 shares of Perspective Therapeutics worth $39.9K as of Q2 2026.
  • Perspective Therapeutics was a new Graham Capital Management position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1208 holding.
  • Graham Capital Management first reported a position in Perspective Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Graham Capital Management's Perspective Therapeutics position peaked at $221K in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.